Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03744676
Other study ID # 017007
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 29, 2018
Est. completion date September 22, 2023

Study information

Verified date December 2023
Source Juno Therapeutics, a Subsidiary of Celgene
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subjects will receive treatment with JCAR017 and will be followed for up to 2 years.


Description:

This is an open-label, multicenter, Phase 2 study to assess the safety and antitumor activity in adult patients with relapsed or refractory B-cell non-Hodgkin Lymphoma when administered with lisocabtagene maraleucel (JCAR017) in the outpatient setting. Upon the successful product generation of lisocabtagene maraleucel, subjects will enter the treatment phase of the study. Treatment will include lymphodepleting chemotherapy followed by lisocabtagene maraleucel administration. Subjects will then enter the post-treatment follow-up phase of the study and will be followed for approximately 24 months for safety, disease status, health-related quality of life (HRQoL), and survival. Long-term follow-up will continue under a separate long-term follow-up protocol, per health regulatory authority guidelines, currently up to 15 years after the last lisocabtagene maraleucel administration.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date September 22, 2023
Est. primary completion date September 22, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years at the time of consent - Relapsed or refractory B-cell NHL of the following histologies: diffuse large B cell lymphoma (DLBCL) not otherwise specified; includes biopsy-confirmed transformed DLBCL from indolent histologies, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology, primary mediastinal B-cell lymphoma(PMBCL), and follicular lymphoma Grade 3B. Subjects must have been treated with an anthracycline and rituximab (or other CD20-targeted agent) and have relapsed or refractory disease after at least 2 systemic lines of therapy for DLBCL or after auto-HSCT. - Positron-emission tomography-positive disease by Lugano Classification - Eastern Cooperative Oncology Group performance status of 0 to 1 - Adequate bone marrow, renal, hepatic, pulmonary, cardiac organ function - Adequate vascular access for leukapheresis procedure - Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy - Subjects must agree to use appropriate contraception. Exclusion Criteria: - Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study) - History of prior allogeneic hematopoietic stem cell transplant - Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis - History of another primary malignancy that has not been in remission for at least 2 years.The following are examples of exceptions from the 2-year limit: nonmelanoma skin cancer, definitively-treated stage 1 solid tumor with a low risk of recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on a Papanicolau smear. - Active hepatitis B or hepatitis C infection at the time of screening - History of or active human immunodeficiency virus infection at the time of screening - Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate anti-infection treatment at the time of leukapheresis or lisocabtagene maraleucel administration - Presence of acute or chronic graft-versus-host disease - History of clinically significant cardiac conditions within the past 6 months - History or presence of clinically relevant CNS pathology such as epilepsy/seizure, paresis, aphasia, stroke, cerebral edema, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis - Pregnant or nursing women - Subject does not meet protocol-specified washout periods for certain prior treatments - Prior CAR T-cell or other genetically modified T-cell therapy - Progressive vascular tumor invasion, thrombosis, or embolism - Venous thrombosis or embolism not managed on stable regimen of anticoagulation - Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol

Study Design


Intervention

Biological:
lisocabtagene maraleucel
lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection

Locations

Country Name City State
United States Local Institution - 0041 Albany New York
United States Local Institution - 0039 Cincinnati Ohio
United States Local Institution - 0097 Dallas Texas
United States Local Institution - 0060 Denver Colorado
United States Local Institution - 0052 East Brunswick New Jersey
United States Local Institution - 0098 Eugene Oregon
United States Local Institution - 0037 Greenville South Carolina
United States Local Institution - 0065 Indianapolis Indiana
United States Lancaster General Hospital Lancaster Pennsylvania
United States Local Institution - 0057 Los Angeles California
United States Local Institution - 0064 Louisville Kentucky
United States Local Institution - 0089 Miami Florida
United States Local Institution - 0066 Morristown New Jersey
United States Local Institution - 0063 Nashville Tennessee
United States Local Institution - 0036 Norfolk Virginia
United States Local Institution - 0081 Orlando Florida
United States Local Institution - 0051 Portland Oregon
United States Local Institution - 0074 Salt Lake City Utah
United States Local Institution - 0061 San Antonio Texas
United States Local Institution - 0101 Southfield Michigan
United States Baylor Scott and White Health Temple Texas
United States Local Institution - 0096 Tyler Texas
United States Local Institution - 0069 Wichita Kansas

Sponsors (2)

Lead Sponsor Collaborator
Juno Therapeutics, a Subsidiary of Celgene Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade = 3 Cytokine release syndrome is characterized by high fever, fatigue, nausea, headache, dyspnea, tachycardia, rigors, hypotension, hypoxia, myalgia/arthralgia, and anorexia.
Incidence of Grade = 3 CRS, based on the TEAE with MedDRA PT "Cytokine release syndrome," graded according to the grading scale adapted from Lee (Lee 2014).
From first dose to 90 days following first dose (up to approximately 90 days)
Primary Percentage of Participants With Neurotoxicity (NT) Adverse Events Grade = 3 NT events have also been reported and may include neurologic symptoms such as altered mental status, aphasia, altered level of consciousness, and seizures or seizure-like activity.
Incidence of Grade = 3 NT, defined as an Investigator-identified TEAE considered neurotoxicity related to JCAR017.
From first dose to 90 days following first dose (up to approximately 90 days)
Primary Percentage of Participants With Infection Adverse Events Grade = 3 Incidence of treatment-emergent Grade = 3 infections, defined using MedDRA SOC. From first dose to 90 days following first dose (up to approximately 90 days)
Primary Percentage of Participants With Prolonged Grade = 3 Cytopenia at Day 29. Prolonged cytopenia is defined as the occurrence of Grade = 3 cytopenia not resolved by the Day 29 visit, based on laboratory results of low hemoglobin, absolute neutrophil count decreased, and platelet count decreased. The frequency of subjects experiencing each individual laboratory abnormality and the total number with at least 1 abnormality will be summarized, as will recovery from prolonged cytopenia after Day 29. At Day 29 after first treatment
Secondary Number of Participants With Adverse Events From first dose to 90 days following first dose (up to approximately 90 days)
Secondary Number of Participants With Clinically Significant Laboratory Abnormalities- Hematology From first dose to up to 41 months
Secondary Number of Participants With Clinically Significant Laboratory Abnormalities- Chemistry From first dose to up to 41 months
Secondary Number of Participants With Adverse Events Grade = 3 From first dose to 90 days following first dose (up to approximately 90 days)
Secondary Time to Onset and Time to Resolution of Grade = 3 Cytokine Release Syndrome (CRS) From first dose to up to approximately 41 months
Secondary Time to Onset and Time to Resolution of Grade = 3 Neurotoxicity (NT) From first dose to up to approximately 41 months
Secondary Number of Participants Administered Tocilizumab and Corticosteroid for Management of Cytokine Release Syndrome (CRS) From first dose to up to approximately 41 months
Secondary Number of Participants Administered Tocilizumab and Corticosteroid for Management of Neurotoxicity (NT) From first dose to up to approximately 41 months
Secondary Objective Response Rate (ORR) The Percentage of participants with a best overall response (BOR) of either CR or PR based on the Lugano 2014 criteria.
Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification"
Complete response is defined as:
Score 1, 2, or 3a with or without residual mass
No evidence of FDG-avid disease in marrow
Partial Response is defined as:
Score 4 or 5a with reduced uptake compared with baseline and residual masses of any size
Bone marrow with residual uptake higher than in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in marrow in the context of a nodal response, should consider further evaluation with MRI, biopsy, or interval scan.
From first dose to up to approximately 41 months
Secondary Complete Response Rate (CRR) The Percentage of participants with a best overall response (BOR) with CR based on the Lugano 2014 criteria.
Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification"
Complete response is defined as:
Score 1, 2, or 3a with or without residual mass
No evidence of FDG-avid disease in marrow
From first dose to up to approximately 41 months
Secondary Duration of Response (DoR) and Duration of Complete Response (DoCR) Duration of response (DOR) is defined as the time from the first documentation of response (CR or PR) after JCAR017 infusion to disease progression or death from any cause, whichever occurs first.
Duration of response (DOR) if BOR is CR is defined for subjects with a BOR of CR as the time from the first documentation of response (CR or PR) after JCAR017 infusion to earlier of disease progression or death from any cause.
From first dose to up to approximately 41 months
Secondary Progression Free Survival (PFS) Progression-free survival is defined as the time from infusion of JCAR017 to progressive disease or death, whichever is earlier. If a subject does not have an event for the PFS analysis, the subject will be censored.
Progressive Disease is defined as:
Score 4 or 5a with an increase in intensity of uptake from nadir
New FDG-avid foci consistent with lymphoma (may need biopsy or repeat scan if uncertain about etiology of foci).
Investigator assessed clinical progression
From first dose to up to approximately 41 months
Secondary Overall Survival (OS) Overall survival is defined as the time from infusion of JCAR017 to the date of death. For assessment of OS, data from surviving participants will be censored at the last time that the participant is known to be alive. The OS analysis will include all available survival information from the long-term follow-up study if applicable. From first dose to up to approximately 41 months
Secondary Area Under the Blood Concentration-time Curve From Time to Zero to 28 Days After Dosing AUC (0-28) 28days after first dose
Secondary Maximum Observed Blood Concentration (Cmax) 28days after first dose
Secondary Time of Maximum Observed Blood Concentration (Tmax) 28days after first dose
Secondary European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A higher scale score represents a higher level of well-being and better ability of daily functioning. Thus, a high score for a functional scale represents a high/healthy level of functioning; a high score for the global health status/HRQoL represents a high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatic problem. From Enrollment to end of follow up, approximately 26 months
Secondary EuroQol Instrument EQ-5D-5L. EQ-5D is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). Enrollment to end of follow up, approximately 26 months
Secondary Number of Intensive Care Unit (ICU) Inpatient Days and Non-ICU Inpatient Days and Reasons for Hospitalization Length of initial ICU and non-ICU stay from liso-cel administration From first hospitalization to the last. Approximately 31 days
Secondary Number of Participants Transfused and the Number of Transfusions Per Participant. From first dose to end of treatment period approximately 24 months
Secondary Number of Participants Requiring Growth Factor Support. From first dose to end of treatment period approximately 24 months
Secondary Number of Participants Requiring Intravenous Immunoglobulin (IVIG) Support From first dose to end of treatment period approximately 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1